---
title: "Zhao Yan New Drug rises over 4% amid CRO sector rally"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293545652.md"
description: "Zhao Yan New Drug (6127.HK) climbed 4.15% to HK$25.520 during trading, lifted by CRO sector gains and rising lab monkey prices."
datetime: "2026-07-23T02:00:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293545652.md)
  - [en](https://longbridge.com/en/news/293545652.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293545652.md)
generator: "portal-rs"
---

# Zhao Yan New Drug rises over 4% amid CRO sector rally

Zhao Yan New Drug (6127.HK) **climbed** **4.15%** in Hong Kong trading to **HK$25.520**.

The rise followed a broader rally in the A-share CRO sector. Market attention has also focused on surging lab monkey prices, which are expected to boost earnings for CRO firms holding relevant biological assets. Zhao Yan New Drug anticipates a significant increase in net profit for the first half of the year, driven primarily by the appreciation of its biological assets.

### Related Stocks

- [06127.HK](https://longbridge.com/en/quote/06127.HK.md)

## Related News & Research

- [Is Pop Mart International Group (SEHK:9992) Undervalued On Strong Half Year Earnings?](https://longbridge.com/en/news/296862687.md)
- [Pop Mart grants 137,510 share awards under post-IPO scheme](https://longbridge.com/en/news/296779679.md)
- [Zhipu identifies Ox Alpha as GLM-5.3-Flash and releases model weights](https://longbridge.com/en/news/297138298.md)
- [Ivonescimab regimen shows OS superiority in Phase III HARMONi-GI1, Summit Therapeutics notes](https://longbridge.com/en/news/297053863.md)
- [AKESO  Ivonescimab Plus Chemotherapy Phase III Study Meets Primary Overall Survival Endpoint](https://longbridge.com/en/news/296969973.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**